SLC5A2 and type 2 diabetes mellitus: Collectively, the available data provide a strong rationale for further research into the therapeutic targeting of the NO–cGMP pathway for the management of T2DM and obesity, although the promise shown in recent studies with ERAs (Dhaun & Webb, 2019) and sodium–glucose cotransporter 2 (SGLT2) inhibitors (Perkovic, Jardine et al., 2019) in patients with T2DM and renal disease serves to make this a competitive field, to the benefit of future patients.